Studying immune cells and a new treatment for ARDS
Part of Lungs & breathing clinical trials.
This study looks at how the immune system responds in people with ARDS (a severe lung injury) and tests a new treatment called PIP-2 in the lab to see if it might help. It aims to better understand lung injury and find new ways to treat it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have ARDS (Acute Respiratory Distress Syndrome), a serious lung condition.
- Your ARDS should be mild, moderate, or severe based on blood oxygen levels.
- You cannot be pregnant.
- You must be an adult (18 years or older).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for patients in the ICU with ARDS (a severe lung condition). It looks at biomarkers (special substances in your blood) to help understand different types of ARDS. You do not receive any treatment, but you help researchers learn more about the disease.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This study examines lung fluid samples and imaging scans from patients on breathing machines to better understand acute respiratory distress syndrome (ARDS), a serious lung condition. Researchers hope this will help doctors diagnose and treat ARDS more effectively in the future.
This trial tests a new medicine called GKL-006RTU for people with moderate to severe ARDS caused by an infection. The goal is to see if it is safe and helps improve breathing and recovery.
This study collects health information from ICU patients with or at high risk for ARDS to better understand the condition and develop a tool to help doctors make decisions. It may not directly help you, but it could improve care for future patients.
This trial studies how immune cells in the lungs and gut microbes (your microbiome) change during ARDS and how these changes relate to your outcomes. It may help researchers better predict and treat ARDS by learning what’s going on in the lungs and body systems.
Hear when a new ARDS (Acute Respiratory Distress Syndrome) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.